New Two-Pronged attack on deadly lung cancer subtype
NCT ID NCT07200947
Summary
This study is testing a new combination treatment for a fast-growing type of lung cancer called SMARCA4-deficient NSCLC. It will give patients a new dual-action immunotherapy drug (QL1706) along with standard platinum-based chemotherapy as their first treatment. The main goals are to see if this combination can better control the cancer and is safe for this specific group of patients who currently have very limited treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital
Beijing, Beijing Municipality, China
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.